Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 191–200, page 20 of 20. Filter these by subject, year and score in the research library →

1. Avanços na doença de Alzheimer: diagnóstico precoce, biomarcadores e perspectivas futurasResearch summary

   Research summaries · alzhub.org/study/avancos-na-doenca-de-alzheimer-diagnostico-precoce-biomarcadores-e-3d634112

   … monoclonais como aducanumabe e lecanemab, mostraram-se promissoras em retardar a progressão da doença, mas a acessibilidade e o custo continuam sendo as principais barreiras. Conclusão: Embora tenham sido feitos progressos …

2. Determining eligibility for anti‐amyloid treatments using blood biomarkersResearch summary

   Research summaries · alzhub.org/study/determining-eligibility-for-antiamyloid-treatments-using-blood-41442134

   … anti-amyloid antibody lecanemab. The median APS2 value in the treated sub-cohort was 97, with 75% of patients having an APS2 of 87 or higher. Twenty-one patients additionally underwent either amyloid PET or CSF testing (Figure …

3. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefitResearch summary

   Research summaries · alzhub.org/study/donanemab-another-anti-alzheimer-s-drug-with-risk-and-uncertain-38830549

   … antibodies, aducanumab and lecanemab, respectively. Approval of a third antibody, donanemab, is pending. Moreover, lecanemab and donanemab are claimed to cause delay in the cognitive decline that characterizes the disease. We …

4. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysisResearch summary

   Research summaries · alzhub.org/study/efficacy-and-safety-of-anti-amyloid-monoclonal-antibodies-in-current-37423541

   … Aducanumab, Solanezumab and Lecanemab. The results of this study suggest that anti-Aβ mAbs statistically improved cognitive and biomarker outcomes, particularly Aducanumab and Lecanemab. However, while cognitive effects were of …

5. Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA ProteinResearch summary

   Research summaries · alzhub.org/study/exploring-natural-compounds-for-alzheimer-s-disease-virtual-screening-a3b419d0

   … monoclonal antibodies like Lecanemab, Aducanumab, and Donanemab, have garnered FDA approval but remain controversial due to limited clinical benefits and significant side effects against Alzheimer. The present theorical work …

6. FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer DiseaseResearch summary

   Research summaries · alzhub.org/study/fdg-pet-and-mri-for-monitoring-immunotherapy-in-alzheimer-disease-37314733

   … purpose, aducanumab and lecanemab. In both cases, the approval was based on a presumed therapy-related removal of amyloid deposits from the brain and, in the case of lecanemab, also some delay in cognitive decline. We question …

7. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugsResearch summary

   Research summaries · alzhub.org/study/guidelines-for-pharmacotherapy-in-alzheimer-s-disease-a-primer-on-fda-38059250

   … once every 4 weeks and lecanemab once every 2 weeks. The decision on the choice of the drug must be made after considering the availability of drug, compliance of patient (once-daily vs. multiple doses daily), cost, specific …

8. Implementation and service impact of anti-amyloid therapy in a psychiatry-led dementia care program: Real-world evidence from a Japanese regional dementia centerResearch summary

   Research summaries · alzhub.org/study/implementation-and-service-impact-of-anti-amyloid-therapy-in-a-42019137

   … monoclonal antibody therapy (lecanemab and donanemab), and associated reimbursement and acquisition costs between May 2024 and January 2026. This study was conducted as part of institutional quality improvement activities. During …

9. Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence studyResearch summary

   Research summaries · alzhub.org/study/incidence-of-amyloid-related-imaging-abnormalities-and-health-41885326

   … antibodies (eg, aducanumab, lecanemab, and donanemab) for Alzheimer disease (AD) were shown to increase the risks of amyloid-related imaging abnormalities (ARIA) in randomized clinical trials, which can include brain swelling or …

10. Leqembi Recommended for Treatment of Early Alzheimer's Disease (CHMP re-examination, reversing July 2024 refusal)Research summary

    Research summaries · alzhub.org/study/leqembi-recommended-for-treatment-of-early-alzheimer-s-disease-chmp-6280b4fa

    … initially refused to approve lecanemab in the EU in July 2024, judging that its modest effect on cognitive decline did not outweigh ARIA risk in the broad early-Alzheimer's population studied. After Eisai requested a …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.